A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.

Standard treatment of advanced ovarian cancer is a combination of surgery and chemotherapy. Additional therapies using the i.p. route are considered as a potential means of improving the locoregional control rate. This Phase II study evaluated the efficacy of i.p. radioimmunotherapy (RIT) in patients with minimal residual ovarian adenocarcinoma after primary treatment with surgery and chemotherapy. Between February 1995 and March 1996, six patients with residual macroscopic (<5 mm) or microscopic disease as demonstrated by laparotomy and multiple biopsies received i.p. RIT. All had initial stage III epithelial carcinoma and were treated with debulking surgery and one line (four patients) or two lines (two patients) of chemotherapy. RIT was performed with 60 mg of OC 125 F(ab')2 monoclonal antibody labeled with 4.44 GBq (120 mCi) of 131I injected 5-10 days after the surgical procedure. Systematic laparoscopy or laparotomy with multiple biopsies performed 3 months after RIT in five patients (clinical progression was seen in one patient) showed no change in three patients and progression in two patients. Toxicity was mainly hematological, with grade III neutropenia and thrombocytopenia in two patients. Human antimouse antibody production was demonstrated in all six patients. This study showed little therapeutic benefit from i.p. RIT in patients with residual ovarian carcinoma.

[1]  E. Seregni,et al.  Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. , 1995, European journal of cancer.

[2]  H. Haisma,et al.  Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors. , 1988, American journal of obstetrics and gynecology.

[3]  V. Zurawski,et al.  Intraperitoneal radiolabeled OC125 in patients with advanced ovarian cancer , 1990 .

[4]  J. Schlom,et al.  Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. , 1997, Gynecologic oncology.

[5]  W. Creasman,et al.  THE PROGNOSTIC VALUE OF PERITONEAL CYTOLOGY IN GYNECOLOGIC MALIGNANT DISEASE , 1972 .

[6]  P. Rose,et al.  Intraperitoneal therapy of ovarian cancer with Yttrium-90-labeled monoclonal antibodies : preliminary observations , 1991 .

[7]  J. Chatal,et al.  Use of multi‐cell spheroids of ovarian carcinoma as an intraperitoneal radio‐immunotherapy model: Uptake, retention kinetics and dosimetric evaluation , 1992, International journal of cancer.

[8]  S. Stewart,et al.  Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  V. Zurawski,et al.  Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. , 1992, Gynecologic oncology.

[10]  M. Slevin,et al.  The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy. , 1988, British Journal of Cancer.

[11]  Johnson Wd.  The cytological diagnosis of cancer in serous effusions. , 1966 .

[12]  W. Johnson.  The cytological diagnosis of cancer in serous effusions. , 1966, Acta cytologica.

[13]  P. Fumoleau,et al.  Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. , 1989, Cancer research.

[14]  M. Sullivan,et al.  Intraperitoneal radioimmunotherapy for ovarian cancer , 1989 .

[15]  V. Abeler,et al.  Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of Ovarian cancer , 1992, Cancer.

[16]  M. Slevin,et al.  Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration. , 1987, Cancer research.

[17]  J. Belinson,et al.  False‐Negative Peritoneal Cytology in Metastatic Ovarian Carcinoma , 1986, Obstetrics and gynecology.

[18]  A. Maraveyas,et al.  Asbestos fibers in the colonic wall. , 1974, British Journal of Cancer.

[19]  J. Neijt,et al.  Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. , 1991, European journal of cancer.

[20]  B. Piura,et al.  [Second-look laparotomy in ovarian cancer]. , 1987, Harefuah.

[21]  P. Saigo,et al.  Peritoneal Cytology as an Indicator of Disease in Patients With Residual Ovarian Carcinoma , 1988, Obstetrics and gynecology.

[22]  D. Snook,et al.  Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. , 1989, International journal of radiation oncology, biology, physics.

[23]  W. Mason,et al.  Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions. , 1990, The British journal of cancer. Supplement.

[24]  B. Atkinson,et al.  Peritoneal washing cytology. Uses and diagnostic criteria in gynecologic neoplasms. , 1984, Acta cytologica.

[25]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[26]  V. Torri,et al.  Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.